Navigation Links
Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
Date:7/27/2009

y this result and will be working closely with our clinical team to evaluate these data and the available data from MAESTRO-02 and MAESTRO-03 to determine our next steps," said Kevin Giese, President and CEO of BioMS Medical. "We are fortunate to have suitable resources in place to remain flexible to pursue whatever options emerge once we understand these results more fully."

BioMS Medical Webcast

Participants may listen to a discussion of the outcome of the MAESTRO-01 study by Kevin Giese, President and CEO of BioMS Medical. The audio webcast is accessible through the Company's web site at www.biomsmedical.com.

About MAESTRO-01

MAESTRO-01 was a multi-center, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of dirucotide in patients with SPMS. The study was conducted in Canada and nine countries in Europe and included 612 patients being administered either dirucotide or placebo intravenously every six months for a period of two years.

The primary clinical endpoint for the trial was defined as a statistically significant increase in the time to progression of the disease, as measured by the EDSS, in patients with HLA-DR2 and/or HLA-DR4 immune response genes. It is estimated that up to 70% of all multiple sclerosis patients are HLA-DR2 and/or HLA-DR4 positive(i). The EDSS is the standard for measuring impairment in MS.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, progressive, often disabling disease that attacks the central nervous system(ii). MS is caused by damage to myelin, the protective sheath surrounding nerve fibers in the central nervous system, resulting in disrupted nerve impulses traveling to and from the brain and spinal cord(iii). Symptoms of MS may include vision problems, loss of balance, numbnes
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer
2. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
3. MADIT-CRT Trial Meets Primary Endpoint
4. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
5. Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis
6. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
7. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
8. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
9. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
10. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
11. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
(Date:12/22/2014)... , Dec. 22, 2014  ConvaTec, a privately-held medical ... has been appointed Interim Chief Executive Officer of the ... succeeds Ken Berger .  "The Board of Directors ... leading ConvaTec over the past three years," said ... Directors.  "We are confident that the company is well ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... received 510(k) clearance from the U.S. Food and Drug ... spot scanning. Spot scanning is a proton therapy delivery ... the tumor by using thousands of small individual beamlets ... Intensity Modulated Proton Therapy (IMPT). XiO, Elekta,s ...
... 3, 2010 Halozyme Therapeutics, Inc. (Nasdaq: ... commercializing products targeting the extracellular matrix , today ... serve as president and CEO, effective immediately. Jonathan E. ... of the board of directors to pursue other opportunities. ...
Cached Medicine Technology:Elekta Receives FDA 510(k) Clearance for XiO Software to Plan Spot Scanning for Proton Therapy 2Halozyme Therapeutics Realigns Management 2Halozyme Therapeutics Realigns Management 3
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- A lab technician ... may have been exposed to the Ebola virus in ... And up to a dozen other lab workers are ... Wednesday afternoon. The possible exposure occurred Monday when ... sample of the potentially lethal virus to another CDC ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Gluten, a ... on those who have an intolerance to gluten, causing ... gas, bloating, migraine headaches, joint pain and fatigue. For ... diet plans that deliver safe and fast weight ... that trigger a gluten allergy reaction. These gluten free ...
(Date:12/24/2014)... Jacksonville, Florida (PRWEB) December 24, 2014 The ... a safer place to raise families. In-Vest USA ... those who protect us – our first responders. Today, these ... law enforcement officers by providing them with body armor through ... like the tragic shootings that happened this past week in ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 24, 2014 ... COC Industry is a professional and in-depth research ... the report introduces COC basic information, including its ... policy analysis, news analysis, etc. This report also ... structure etc. Production is separated by regions, technology ...
(Date:12/24/2014)... FL (PRWEB) December 24, 2014 There’s a ... days. With the Republican Party now in control of the ... again for the Affordable Care Act. A lawsuit has been ... delays of certain provisions in the ACA have resulted in ... Also, a Supreme Court hearing will take place to weigh ...
Breaking Medicine News(10 mins):Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3Health News:The Healthy Home Company and In-Vest USA Team Up to Save the Lives of Law Enforcement 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3
... Travel Advantage Network , one of the nation,s ... Susan G. Komen for the Cure , the global leader ... pin sales and a Jeans Day, where employees purchase the ... employees raised $729 for Susan G. Komen for the Cure, ...
... 22 McAuley Ministries, the new grant-making arm of ... first grant... and the recipient is the YMCA of ... the construction of a green rooftop terrace for the ... new Thelma Lovette YMCA touches several of McAuley Ministries ...
... Aurora Health Care announced today that,the physicians ... join Aurora Medical Group. , ... Paul,Guzzetta, M.D., and Mark Plumb, M.D. All are board-certified ... specializes and is,board-certified in the treatment of sleep disorders. ...
... In the year following Hurricane Katrina, the health of ... of a national sample of older adults not affected ... researchers at the Johns Hopkins Bloomberg School of Public ... most powerful and deadliest hurricanes in U.S. history. Hurricane ...
... the founder and longtime director of the HIV advocacy/education ... Institute of Allergy and Infectious Diseases (NIAID) Director,s Special ... against HIV/AIDS. , Mr. Delaney in 1985 ... public policy information and advocacy organization based in San ...
... , Montreal, January 22, 2009 The ... that preventive treatment with high doses of inhaled corticosteroids ... asthma attacks triggered by colds. Dr. Francine Ducharme, assistant ... Center and a pediatrics professor at the Universit de ...
Cached Medicine News:Health News:Grassroots Group Gets Travel Advantage Network Support 2Health News:YMCA of Greater Pittsburgh Receives $500,000 from McAuley Ministries for New Hill YMCA Roof 2Health News:YMCA of Greater Pittsburgh Receives $500,000 from McAuley Ministries for New Hill YMCA Roof 3Health News:Midwest Pulmonary and Critical Care Associates Will Join Aurora Medical Group 2Health News:Decline in health among older adults affected by Hurricane Katrina 2Health News:NIAID honors AIDS activist Martin Delaney 2Health News:New treatment reduces severity of asthma attacks in preschoolers 2